Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

French Validation of the Recovery Assessment Scale (RAS-FR) (VAL-RAS-FR)

22 de agosto de 2026 actualizado por: Etablissement Public de Santé Mentale de Metz-Jury

Cross-Cultural Adaptation, French Validation, and Development of Derived Versions of the Recovery Assessment Scale (RAS) for the Assessment of Subjective Recovery in Mental Health

The VAL-RAS-FR study aims to cross-culturally adapt, validate, and develop derived versions of the Recovery Assessment Scale (RAS), an internationally used self-report measure of subjective recovery in mental health. The study will include 260 adult psychiatric patients receiving care at EPSM Metz-Jury in both inpatient and outpatient settings. Participants will complete the French version of the RAS (RAS-FR), the WHOQOL-BREF, and additional self-report questionnaires. A subgroup of participants will complete the RAS-FR again after one month to assess test-retest reliability. The study will also explore existential aspects of recovery through the development of the RAS-FR-EX (Existential Extension) and support the development of a shorter version, the RAS-FR-SF (Short Form), for clinical and research purposes.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

Recovery in mental health extends beyond symptom reduction and includes hope, self-confidence, autonomy, meaning, and continuity of self. As described by Anthony (1993) and further developed through the CHIME framework, recovery is a deeply personal process involving connectedness, hope, identity, meaning, and empowerment. Although French translations of the Recovery Assessment Scale (RAS) have been used previously, no comprehensive psychometric validation of a French version is currently available for routine use in French-speaking psychiatric settings.

VAL-RAS-FR is a monocentric, prospective, observational study designed to cross-culturally adapt, validate, and develop derived versions of the 41-item Recovery Assessment Scale (RAS) for use in French-speaking mental health settings. The study will enroll 260 adult psychiatric patients receiving care at EPSM Metz-Jury, including patients from inpatient units, day hospital settings, community mental health centers (CMP), and EPSIAD follow-up services. Participants will complete self-report questionnaires including the French version of the RAS (RAS-FR), the WHOQOL-BREF, and complementary questionnaires exploring factors associated with subjective recovery. A subgroup of 50 participants will complete the RAS-FR again after one month to assess test-retest reliability.

The study has three complementary objectives. First, it aims to evaluate the psychometric properties of the French version of the RAS, including validity, internal consistency, dimensional structure, and test-retest reliability. Second, it will explore an existential dimension of recovery through the development of the RAS-FR-EX (Existential Extension), an exploratory extension designed to assess aspects such as continuity of self, reconstruction of meaning, and the experience of existing after psychological crisis. Third, it will support the exploratory development of a shorter version of the scale, the RAS-FR-SF (Short Form), intended to facilitate future clinical use while preserving the core dimensions of subjective recovery.

The study does not involve any modification of usual care, invasive procedures, or additional medical examinations. By combining psychometric validation with exploratory clinical development, VAL-RAS-FR aims to provide a validated French-language measure of subjective recovery, improve the assessment of recovery-oriented outcomes in psychiatric care, and contribute to the development of clinically useful tools for French-speaking mental health services.

Tipo de estudio

De observación

Inscripción (Estimado)

260

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Audrey WILLIG, Psychologist
  • Número de teléfono: +33695082545
  • Correo electrónico: audrey.willig@gmail.com

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

    • Moselle
      • Jury, Moselle, Francia, 57245
        • Reclutamiento
        • EPSM Metz-Jury
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Método de muestreo

Muestra no probabilística

Población de estudio

Adult psychiatric patients receiving care at EPSM Metz-Jury in inpatient units, day hospital settings, community mental health centers (CMP), or through intensive home-based psychiatric care services (EPSIAD). Participants are French-speaking adults able to complete self-report questionnaires independently or with assistance if needed. Patients under legal protection measures may participate in accordance with applicable regulations.

Descripción

Inclusion Criteria:

  • Adult patient (18 years or older)
  • Receiving psychiatric care at EPSM Metz-Jury (inpatient unit, day hospital, community mental health center [CMP], or intensive home-based psychiatric care service [EPSIAD]/post-EPSIAD follow-up)
  • Able to understand French
  • Able to complete a self-report questionnaire independently or with assistance if needed
  • Patients under legal protection measures (guardianship or curatorship) may participate with the agreement of their legal representative, when applicable

Exclusion Criteria:

  • Major cognitive impairment
  • Severe clinical condition preventing questionnaire completion or understanding of French
  • Refusal to participate
  • Prisoner or person deprived of liberty by judicial or administrative decision

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Adult psychiatric patients
Adult psychiatric patients receiving care at EPSM Metz-Jury (inpatient units, day hospital, community mental health centers [CMP], and intensive home-based psychiatric care services [EPSIAD]) who are able to complete self-report questionnaires in French.
Participants complete self-report questionnaires including the French version of the Recovery Assessment Scale (RAS-FR), the WHOQOL-BREF, and complementary questionnaires related to subjective recovery. The study also includes the exploratory assessment of six additional existential items. A subgroup of 50 participants will complete the RAS-FR again after one month to assess test-retest reliability. No therapeutic intervention, modification of usual care, invasive procedure, or additional medical examination is involved.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Recovery Assessment Scale - French Version (RAS-FR): Total Score, Internal Consistency, Factor Structure, and Test-Retest Reliability
Periodo de tiempo: Baseline and 1 month
The Recovery Assessment Scale - French Version (RAS-FR) is a 41-item self-report questionnaire assessing subjective recovery in mental health. Total scores range from 41 to 205, with higher scores indicating a higher level of subjective recovery. Psychometric analyses will include internal consistency, dimensional structure, and test-retest reliability.
Baseline and 1 month

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Correlation between Recovery Assessment Scale - French Version (RAS-FR) and WHOQOL-BREF (World Health Organization Quality of Life - Brief Version) scores
Periodo de tiempo: Baseline
Assessment of convergent validity through correlations between the Recovery Assessment Scale - French Version (RAS-FR) total score and WHOQOL-BREF domain scores in adult psychiatric patients, with particular attention to the psychological and social relationship domains. The RAS-FR total score ranges from 41 to 205, with higher scores indicating a higher level of subjective recovery. WHOQOL-BREF domain scores range from 0 to 100, with higher scores indicating better perceived quality of life. Pearson or Spearman correlation coefficients will be calculated.
Baseline
Existential dimension of recovery (RAS-FR-EX) composite score
Periodo de tiempo: Baseline
Exploratory assessment of the existential dimension of recovery using six additional items integrated into the French version of the Recovery Assessment Scale (RAS-FR-EX). A composite score ranging from 6 to 30 will be calculated, with higher scores indicating a stronger endorsement of existential recovery processes.
Baseline
Development of a short-form Recovery Assessment Scale - French Version (RAS-FR-SF)
Periodo de tiempo: Baseline
Exploratory item reduction analyses based on responses to the 41-item Recovery Assessment Scale - French Version (RAS-FR). The objective is to identify a shorter version of the instrument while preserving its psychometric properties and conceptual coverage of subjective recovery.
Baseline

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Audrey WILLIG, Psychologist, Clinical Research Unit (URC), EPSM Metz-Jury

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

29 de junio de 2026

Finalización primaria (Estimado)

1 de enero de 2027

Finalización del estudio (Estimado)

1 de septiembre de 2027

Fechas de registro del estudio

Enviado por primera vez

16 de junio de 2026

Primero enviado que cumplió con los criterios de control de calidad

19 de junio de 2026

Publicado por primera vez (Actual)

25 de junio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

26 de agosto de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

22 de agosto de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • EPSM-VAL-RAS-FR
  • 2026-A00601-50 (Otro identificador: ANSM)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Individual participant data (IPD) will not be made publicly available. Access to study data may be considered on a case-by-case basis upon request to the sponsor, subject to regulatory requirements, confidentiality obligations, and GDPR compliance.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .